Replimune Group Inc REPL

US Biotechnology

$11.20 ▲ +107.02% (+$5.79)

⬆️ Above Yest. High 🔥 High Short Interest 📅 Earnings This Week

Open $11.38

Prev Close $5.41

Day Range $9.43 – $12.50

52W Range $1.50 – $12.50

Market Cap $454.58M

Beta 0.89

EPS (TTM) $-3.39

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2018-07-20
Shares Out.	84,030,000
Website	replimune.com/ ↗
Phone	13026587581
Employees	465
Net Income	-$73.2M
Free Cash Flow	-$284.6M
Total Assets	$332.4M
Total Liabilities	$166.2M
Equity	$166.2M

About Replimune Group Inc

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Replimune Group Inc is a publicly traded company under the ticker symbol REPL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.